Bayer Aktiengesellschaft (BAYZF)
| Market Cap | 57.30B +166.1% |
| Revenue (ttm) | 53.81B -1.9% |
| Net Income | -232.31M |
| EPS | -0.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 9.88 |
| Dividend | 0.13 (0.22%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | n/a |
| Average Volume | 14,464 |
| Open | 53.80 |
| Previous Close | 58.15 |
| Day's Range | 53.80 - 53.80 |
| 52-Week Range | 20.99 - 58.33 |
| Beta | 0.97 |
| RSI | 79.87 |
| Earnings Date | Mar 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial numbers in EUR Financial StatementsNews
Bayer agrees to $7.25bn proposed settlement over Roundup weedkiller lawsuits
Thousands of lawsuits accuse the agrochemical maker of failing to warn people that its weedkiller could cause cancer Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7....
Bayer agrees to US$7.25 billion proposed settlement over thousands of Roundup cancer lawsuits
Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of U.S. lawsuits alleging the company failed to warn people that i...
Bayer offers $7.25bn to settle weedkiller cancer claims
The company has faced years of legal battles over Roundup, a weedkiller made by Monsanto.
Bayer Proposes New $7 Billion Plan to Settle Roundup Litigation
Company says settlement would address bulk of outstanding cases; the Supreme Court has agreed to hear Bayer's appeal to neutralize cancer claims.
Bayer CEO says Roundup settlement is important addition to Supreme Court case
Bayer's U.S. class settlement aimed at resolving current and future claims that Roundup weedkiller caused non‑Hodgkin lymphoma is an important addition to its Supreme Court case, Bayer CEO Bill Anders...
Bayer (BAYRY) Plans $10.5 Billion Settlement for Roundup Lawsuits
Bayer (BAYRY) Plans $10.5 Billion Settlement for Roundup Lawsuits
Bayer eyes $10.5B settlement effort to resolve U.S. Roundup litigation - Bloomberg
Bayer is preparing to announce a $10.5B settlement push to resolve current and future cancer lawsuits over its Roundup weedkiller, Bloomberg reported.
Bayer to make $10.5 bln push to settle roundup cases, Bloomberg reports
Bayer is planning to announce a $10.5 billion settlement push to settle current and future cancer lawsuits over its Roundup weedkiller, Bloomberg reported on Tuesday, citing people familiar with the p...
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month
WHIPPANY, N.J.--(BUSINESS WIRE)--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to H...
Oakmark International Strategy Q4 2025 Contributors And Detractors
Oakmark International Strategy portfolio's return was 4.93% (net) for the reporting period vs. MSCI World ex USA Index that returned 5.20% for the same period.
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention Transcript
Bayer Aktiengesellschaft (BAYRY) Discusses OCEANIC-STROKE Phase III Results and Asundexian in Secondary Stroke Prevention February 6, 2026 9:00 AM...
DAX Rises After Flat Start; Rheinmetall, Bayer Among Top Gainers
(RTTNews) - After a flat start, Germany stock market's key index DAX moved up smartly on Friday, with stocks from several sectors gaining in strength on sustained buying interest. Concerns about AI-re...
Bayer's (BAYRY) Asundexian Significantly Reduces Stroke Risk in Phase 3 Trial
Bayer's (BAYRY) Asundexian Significantly Reduces Stroke Risk in Phase 3 Trial
Bayer stroke prevention drug asundexian shows positive results in phase 3 trial
Bayer says its experimental blood thinner cuts risk of stroke recurrence by 26%
Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% in a late-stage trial, in a fresh boost for CEO Bill Anderson's turnaround efforts.
Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo
NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibito...
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign.
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar
Bayer to build new canola research and development site in Winnipeg
Bayer says it will put more than $45 million toward building a new research and development facility in Winnipeg.
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada
CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge...
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention
BERLIN--(BUSINESS WIRE)--Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two...
Bayer Announces FDA's Orphan Drug Designation For OpCT-001 To Treat Retinitis Pigmentosa
(RTTNews) - Bayer AG (BYR.L, BAY.MI, BAYN.DE) and its independently operated subsidiary BlueRock Therapeutics LP announced that its investigational cell therapy, OpCT-001, has received Orphan Drug Des...
Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case
BAYRY jumps 6.4% after the Supreme Court agrees to review the Durnell Roundup case, a key test of federal preemption in glyphosate litigation.